Publications by authors named "Kelsey Schwensen"
Importance: Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy of anthracycline-free chemoimmunotherapy in TNBC has not been assessed.
Objective: To assess the efficacy of the anthracycline-free neoadjuvant regimen of carboplatin and docetaxel plus pembrolizumab in TNBC.
Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to investigate the impact of circulating tumor DNA (ctDNA) status and residual cancer burden (RCB) class on outcomes in TNBC patients with RD.
View Article and Find Full Text PDFTriple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression <1% and absence of HER2 amplification/overexpression. HER2-negative breast cancer with low ER/PR expression (1-10%) has a gene expression profile similar to TNBC; however, real-world treatment patterns, chemotherapy response, endocrine therapy benefit, and survival outcomes for the Low-ER group are not well known. 516 patients with stage I-III HER2-negative breast cancer and ER/PR expression ≤10% who were enrolled in a multisite prospective registry between 2011 and 2019 were categorized on the basis of ER/PR expression.
View Article and Find Full Text PDFArticle Synopsis
- Previous studies confirmed that the residual cancer burden (RCB) after neoadjuvant chemotherapy predicts long-term outcomes in breast cancer, leading to a pooled analysis to explore this relationship across various cancer subtypes.
- The analysis involved data from 5161 patients across 12 institutes in Europe and the USA, focusing on their clinical characteristics and the impact of RCB on event-free survival rates.
- Findings highlighted that RCB scores were significant across all breast cancer subtypes, with higher scores correlating to poorer event-free survival outcomes, indicating the importance of RCB in treatment prognosis.
Purpose: mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).
Patients And Methods: Eligible patients had HER2-negative MBC with any number of prior chemotherapies.